227 related articles for article (PubMed ID: 37726806)
1. A urinary assay for mutation and methylation biomarkers in the diagnosis and recurrence prediction of non-muscle invasive bladder cancer patients.
Huang H; Liu A; Liang Y; Xin Y; Liu J; Hao Y; Huang D; Chen L; Li W; Jiang G; Huang Y; Xu Y; Zhang J; Ma T; Xu D; Gao Y
BMC Med; 2023 Sep; 21(1):357. PubMed ID: 37726806
[TBL] [Abstract][Full Text] [Related]
2. Promoter hypermethylation of HS3ST2, SEPTIN9 and SLIT2 combined with FGFR3 mutations as a sensitive/specific urinary assay for diagnosis and surveillance in patients with low or high-risk non-muscle-invasive bladder cancer.
Roperch JP; Grandchamp B; Desgrandchamps F; Mongiat-Artus P; Ravery V; Ouzaid I; Roupret M; Phe V; Ciofu C; Tubach F; Cussenot O; Incitti R
BMC Cancer; 2016 Sep; 16(1):704. PubMed ID: 27586786
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of diagnostic strategies for bladder cancer using computed tomography (CT) urography, flexible cystoscopy and voided urine cytology: results for 778 patients from a hospital haematuria clinic.
Blick CG; Nazir SA; Mallett S; Turney BW; Onwu NN; Roberts IS; Crew JP; Cowan NC
BJU Int; 2012 Jul; 110(1):84-94. PubMed ID: 22122739
[TBL] [Abstract][Full Text] [Related]
4. Performance of the Bladder EpiCheck™ Methylation Test for Patients Under Surveillance for Non-muscle-invasive Bladder Cancer: Results of a Multicenter, Prospective, Blinded Clinical Trial.
Witjes JA; Morote J; Cornel EB; Gakis G; van Valenberg FJP; Lozano F; Sternberg IA; Willemsen E; Hegemann ML; Paitan Y; Leibovitch I
Eur Urol Oncol; 2018 Sep; 1(4):307-313. PubMed ID: 31100252
[TBL] [Abstract][Full Text] [Related]
5. Reducing the Frequency of Follow-up Cystoscopy in Low-grade pTa Non-muscle-invasive Bladder Cancer Using the ADXBLADDER Biomarker.
Rouprêt M; Gontero P; McCracken SRC; Dudderidge T; Stockley J; Kennedy A; Rodriguez O; Sieverink C; Vanié F; Allasia M; Witjes JA; Colombel M; Longo F; Montanari E; Palou J; Sylvester RJ
Eur Urol Focus; 2022 Nov; 8(6):1643-1649. PubMed ID: 35300937
[TBL] [Abstract][Full Text] [Related]
6. Follow-up in non-muscle-invasive bladder cancer-International Bladder Cancer Network recommendations.
Kassouf W; Traboulsi SL; Schmitz-Dräger B; Palou J; Witjes JA; van Rhijn BW; Grossman HB; Kiemeney LA; Goebell PJ; Kamat AM
Urol Oncol; 2016 Oct; 34(10):460-8. PubMed ID: 27368880
[TBL] [Abstract][Full Text] [Related]
7. Non-invasive diagnosis and surveillance of bladder cancer with driver and passenger DNA methylation in a prospective cohort study.
Xiao Y; Ju L; Qian K; Jin W; Wang G; Zhao Y; Jiang W; Liu N; Wu K; Peng M; Cao R; Li S; Shi H; Gong Y; Zheng H; Liu T; Luo Y; Ma H; Chang L; Li G; Cao X; Tian Y; Xu Z; Yang Z; Shan L; Guo Z; Yao D; Zhou X; Chen X; Guo Z; Liu D; Xu S; Ji C; Yu F; Hong X; Luo J; Cao H; Zhang Y; Wang X
Clin Transl Med; 2022 Aug; 12(8):e1008. PubMed ID: 35968916
[TBL] [Abstract][Full Text] [Related]
8. Clinical Validation of the Proenkephalin (
Han H; Oh TJ; Heo JE; Lee J; Jang WS; Lee SH; Ham WS; Hwang J; An S; Choi YD
Eur Urol Open Sci; 2024 Apr; 62():99-106. PubMed ID: 38496823
[TBL] [Abstract][Full Text] [Related]
9. Urine Cytology Rarely Escalates Clinical Management in the Surveillance of Non-muscle-Invasive Bladder Cancer.
Feiertag N; Barry E; Abramson M; Park JY; Kovac E; Aboumohamed A; Watts K; Sankin A
Clin Genitourin Cancer; 2023 Apr; 21(2):258-264. PubMed ID: 36621462
[TBL] [Abstract][Full Text] [Related]
10. HOXA9, PCDH17, POU4F2, and ONECUT2 as a Urinary Biomarker Combination for the Detection of Bladder Cancer in Chinese Patients with Hematuria.
Wu Y; Jiang G; Zhang N; Liu S; Lin X; Perschon C; Zheng SL; Ding Q; Wang X; Na R; Sun J; Xu J
Eur Urol Focus; 2020 Mar; 6(2):284-291. PubMed ID: 30309818
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic accuracy, clinical utility and influence on decision-making of a methylation urine biomarker test in the surveillance of non-muscle-invasive bladder cancer.
D'Andrea D; Soria F; Zehetmayer S; Gust KM; Korn S; Witjes JA; Shariat SF
BJU Int; 2019 Jun; 123(6):959-967. PubMed ID: 30653818
[TBL] [Abstract][Full Text] [Related]
12. Longitudinal follow-up and performance validation of an mRNA-based urine test (Xpert
Cowan B; Klein E; Jansz K; Westenfelder K; Bradford T; Peterson C; Scherr D; Karsh LI; Egerdie B; Witjes A; Trainer A; Harris R; Goldfarb B; Flax S; Kroeger R; Boyd B; Liao J; Patel S; Bridge J; Reuter V; Quigley N; Brown S; Zhao S; Satya M; Bates M; Simon IM; Campbell S; Lotan Y
BJU Int; 2021 Dec; 128(6):713-721. PubMed ID: 33793062
[TBL] [Abstract][Full Text] [Related]
13. Urinary biomarkers for bladder cancer diagnosis and NMIBC follow-up: a systematic review.
Soorojebally Y; Neuzillet Y; Roumiguié M; Lamy PJ; Allory Y; Descotes F; Ferlicot S; Kassab-Chahmi D; Oudard S; Rébillard X; Roy C; Lebret T; Rouprêt M; Audenet F
World J Urol; 2023 Feb; 41(2):345-359. PubMed ID: 36592175
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the performances of the ADXBLADDER test and urinary cytology in the follow-up of non-muscle-invasive bladder cancer: a blinded prospective multicentric study.
Gontero P; Montanari E; Roupret M; Longo F; Stockley J; Kennedy A; Rodriguez O; McCracken SRC; Dudderidge T; Sieverink C; Vanié F; Allasia M; Witjes JA; Sylvester R; Colombel M; Palou J
BJU Int; 2021 Feb; 127(2):198-204. PubMed ID: 32745350
[TBL] [Abstract][Full Text] [Related]
15. Prospective Validation of Clinical Usefulness of a Novel mRNA-based Urine Test (Xpert® Bladder Cancer Monitor) for surveillance in Non Muscle Invasive Bladder Cancer.
Elsawy AA; Awadalla A; Elsayed A; Abdullateef M; Abol-Enein H
Urol Oncol; 2021 Jan; 39(1):77.e9-77.e16. PubMed ID: 32800441
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic Accuracy of Novel Urinary Biomarker Tests in Non-muscle-invasive Bladder Cancer: A Systematic Review and Network Meta-analysis.
Laukhtina E; Shim SR; Mori K; D'Andrea D; Soria F; Rajwa P; Mostafaei H; Compérat E; Cimadamore A; Moschini M; Teoh JY; Enikeev D; Xylinas E; Lotan Y; Palou J; Gontero P; Babjuk M; Witjes JA; Kamat AM; Roupret M; Shariat SF; Pradere B;
Eur Urol Oncol; 2021 Dec; 4(6):927-942. PubMed ID: 34753702
[TBL] [Abstract][Full Text] [Related]
17. DETECT I & DETECT II: a study protocol for a prospective multicentre observational study to validate the UroMark assay for the detection of bladder cancer from urinary cells.
Tan WS; Feber A; Dong L; Sarpong R; Rezaee S; Rodney S; Khetrapal P; de Winter P; Ocampo F; Jalil R; Williams NR; Brew-Graves C; Kelly JD
BMC Cancer; 2017 Nov; 17(1):767. PubMed ID: 29141603
[TBL] [Abstract][Full Text] [Related]
18. Validation of a DNA Methylation-Mutation Urine Assay to Select Patients with Hematuria for Cystoscopy.
van Kessel KE; Beukers W; Lurkin I; Ziel-van der Made A; van der Keur KA; Boormans JL; Dyrskjøt L; Márquez M; Ørntoft TF; Real FX; Segersten U; Malats N; Malmström PU; Van Criekinge W; Zwarthoff EC
J Urol; 2017 Mar; 197(3 Pt 1):590-595. PubMed ID: 27746284
[TBL] [Abstract][Full Text] [Related]
19. A Genomic Urine Assay for Surveillance of Patients with Bladder Cancer Treated with Radiotherapy.
de Jong FC; Iflé IG; van der Made AC; Kooper D; de Jong JJ; Franckena M; Zuiverloon TCM; van Criekinge W; Incrocci L; Zwarthoff EC; Boormans JL
Eur Urol Open Sci; 2024 Apr; 62():131-139. PubMed ID: 38496820
[TBL] [Abstract][Full Text] [Related]
20. A Prospective Blinded Evaluation of Urine-DNA Testing for Detection of Urothelial Bladder Carcinoma in Patients with Gross Hematuria.
Dahmcke CM; Steven KE; Larsen LK; Poulsen AL; Abdul-Al A; Dahl C; Guldberg P
Eur Urol; 2016 Dec; 70(6):916-919. PubMed ID: 27417036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
